NSE - Free Realtime Quote INR

Speciality Restaurants Limited (SPECIALITY.NS)

127.00

-5.34

(-4.04%)

As of 1:41:12 PM GMT+5:30. Market Open.

FTSE 100 LIVE: Markets slide as China accuses US of violating trade deal

Markets were volatile on Monday as Trump's tariff war continues to play out.

Yahoo Finance UK 18 minutes ago

ES=F

^FTSE

^FCHI
Oil Advances as OPEC+ Supply Boost Vies With Geopolitical Risk

(Bloomberg) -- Oil advanced as OPEC+ hiked production less than some had feared and geopolitical concerns flared over Ukraine and Iran.Most Read from BloombergBillionaire Steve Cohen Wants NY to Expand Taxpayer-Backed FerryWhere the Wild Children’s Museums AreThe Economic Benefits of Paying Workers to MoveNow With Colorful Blocks, Tirana’s Pyramid Represents a Changing AlbaniaNYC Congestion Toll Brings In $216 Million in First Four MonthsBrent crude for August rose toward $65 a barrel after losi

Bloomberg 2 hours ago

BZ=F

CL=F
Dollar Likely to Weaken Further on Fading U.S. Exceptionalism, Other Factors

The dollar was likely to weaken further as fading U.S. exceptionalism continues and is expected to persist through 2H, Nomura said.

The Wall Street Journal 2 hours ago

X
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, have entered into an agreement under which Sanofi will acquire Blueprint.

PR Newswire 2 hours ago

BPMC

SNY

SNYNF
Sanofi to buy US biopharma group Blueprint for over $9 billion

PARIS (Reuters) -France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for over $9 billion to boost its position in rare immunology diseases, in what would be the biggest healthcare deal in Europe this year, according to LSEG data. Blueprint is a specialist in treatments for systemic mastocytosis, a rare immunological disorder. The two companies said on Monday that Sanofi would pay $129.00 per share in cash.

Reuters 2 hours ago

SNY

BPMC
Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

The deal includes a drug approved in the U.S. and the EU for systemic mastocytosis, a rare immunology disease, as well as an early-stage immunology pipeline, the companies said.

The Wall Street Journal 2 hours ago

SNY

SNYNF

BPMC
How much does it cost to become a driver in the UK?

Costs include driving lessons, insurance and the car itself — and it all adds up.

Yahoo Finance UK 3 hours ago

GBPUSD=X

USD=X

GBP=X
Watch These U.S. Steel Stock Price Levels as Trump Plans to Double Steel Tariffs

U.S. Steel shares will be in the spotlight to start the week after President Donald Trump on Friday said he plans to double steel and aluminum tariffs to 50%. Monitor these key chart levels.

Investopedia 5 hours ago

X
2 American Companies That Could Be the Winners of Trump's Tariff Wars

Trump's tariff wars have brought outsize uncertainty to the stock market, making it increasingly challenging to identify companies positioned to weather the storm.

Motley Fool 20 hours ago

HD

NUE
Street Calls of the Week

Investing.com -- Here is your Pro Recap of the top takeaways from Wall Street analysts for the past week.

Investing.com 22 hours ago

CLF

MSM

FICO
Institutional investors have a lot riding on BAE Systems plc (LON:BA.) with 82% ownership

Key Insights Given the large stake in the stock by institutions, BAE Systems' stock price might be vulnerable to their...

Simply Wall St. yesterday

BAESF

BAESY
Europe stocks stage world-beating rally as trade war backfires

(Bloomberg) -- Europe’s equities have emerged clear winners worldwide as the region’s economic outlook brightens at a time when President Donald Trump’s trade war hobbles US financial markets.

Bloomberg 11 hours ago

MCO

HAGHY

HNSDF
'Reformer pilates is the top-searched fitness trend — and we're reinventing it'

Founded in 2018 by a husband and wife team, Reform RX set out to create a world-first connected pilates reformer.

Yahoo Finance UK yesterday

HLT

GBPEUR=X

GBP=X
MP Materials (NYSE:MP) Reports Q1 Net Loss Despite Increase In REO Production

MP Materials (NYSE:MP) recently signed a Memorandum of Understanding with the Saudi Arabian Mining Company to develop a rare earth supply chain in Saudi Arabia, aligning with growing global demands. Despite reporting a net loss for the first quarter, the company increased its REO and NdPr production volumes. Additionally, no shares were repurchased in the recent buyback tranche, reflecting existing efforts. Over the past week, the company's share price rose by 11%, notably outperforming the...

Simply Wall St. yesterday

MP
Regeneron Pharmaceuticals (NasdaqGS:REGN) Reports 27% Reduction In COPD Exacerbations In Phase 3 Trial

Regeneron Pharmaceuticals (NasdaqGS:REGN) announced favorable Phase 3 trial results for itepekimab and entered a significant licensing agreement with Telesis Bio, enhancing its R&D capabilities. Despite these positive developments, the company's shares fell by 17% last week. In contrast, the broader market rose by 1.7%. This divergence might suggest that the market's reaction to Regeneron's news was mixed or that other factors were at play. While the trial success and new partnership could...

Simply Wall St. yesterday

REGN
Better AI Stock: Palantir vs. BigBear.ai

Palantir and BigBear.ai are artificial intelligence (AI) stocks involved in the defense industry. Both companies are also working to move beyond the U.S. government. Two of the leading artificial intelligence (AI) stocks over the past year are Palantir Technologies (NASDAQ: PLTR) and BigBear.ai (NYSE: BBAI).

Motley Fool yesterday

PLTR

BBAI-WS

PYPL
Palantir, JPMorgan Chase Lead Five Stocks Near Buy Points

Palantir Technologies has been getting no shortage of good news from the Trump administration as other contractors struggle.

Investor's Business Daily yesterday

EAT

DASH

COST
Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing

Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001) Libtayo also demonstrated 80% and 65% reductions in the risk of locoregional and distant recurrence, respectively, compared to placebo Detailed results presented in an oral session at the 2025 American Society of Clinical Oncology Annual Meeting and simultaneously published in the New England Journal of Medicine Regulatory applications have been submitted in the United St

GlobeNewswire yesterday

REGN
Better Artificial Intelligence Stock: BigBear.ai vs. Palantir

The AI data analytics market could be worth more than $1 trillion by 2033. BigBear.ai is trying to carve out its niche in the space, but sales growth has been disappointing. Palantir's sales are climbing and it's profitable, but its stock is pricey.

Motley Fool yesterday

PLTR

BBAI-WS
Better Artificial Intelligence (AI) Stock: Palantir vs. Snowflake

Shares of both Palantir and Snowflake have delivered healthy gains in 2025 despite the broader stock market weakness. Palantir stock has shot up 63% this year despite bouts of volatility. Palantir Technologies helps commercial and government clients integrate generative AI capabilities into their operations with its Artificial Intelligence Platform (AIP), which was launched roughly two years ago.

Motley Fool yesterday

SNOW

PLTR

Performance Overview

Return	SPECIALITY.NS	S&P BSE SENSEX (^BSESN)
YTD	-9.97%	+4.08%
1-Year	-24.86%	+9.96%
3-Year	-2.81%	+45.70%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Speciality Restaurants Limited (SPECIALITY.NS)

Related News

FTSE 100 LIVE: Markets slide as China accuses US of violating trade deal

Oil Advances as OPEC+ Supply Boost Vies With Geopolitical Risk

Dollar Likely to Weaken Further on Fading U.S. Exceptionalism, Other Factors

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to buy US biopharma group Blueprint for over $9 billion

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

How much does it cost to become a driver in the UK?

Watch These U.S. Steel Stock Price Levels as Trump Plans to Double Steel Tariffs

2 American Companies That Could Be the Winners of Trump's Tariff Wars

Street Calls of the Week

Institutional investors have a lot riding on BAE Systems plc (LON:BA.) with 82% ownership

Europe stocks stage world-beating rally as trade war backfires

'Reformer pilates is the top-searched fitness trend — and we're reinventing it'

MP Materials (NYSE:MP) Reports Q1 Net Loss Despite Increase In REO Production

Regeneron Pharmaceuticals (NasdaqGS:REGN) Reports 27% Reduction In COPD Exacerbations In Phase 3 Trial

Better AI Stock: Palantir vs. BigBear.ai

Palantir, JPMorgan Chase Lead Five Stocks Near Buy Points

Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing

Better Artificial Intelligence Stock: BigBear.ai vs. Palantir

Better Artificial Intelligence (AI) Stock: Palantir vs. Snowflake

Performance Overview